Treatment with Soliris (eculizumab), along with several immune-suppressing medications, was part of a treatment strategy that supported a woman with atypical hemolytic uremic syndrome (aHUS) in receiving a kidney donated from her mother — even though testing showed the two were not fully immunologically compatible. The case was…
News
Doctors successfully used a combination of Ultomiris (ravulizumab) and a blood pressure medication called sacubitril/valsartan to manage a case of atypical hemolytic uremic syndrome (aHUS) complicated by extremely high blood pressure. Researchers said it was the first reported case of the treatment combo being used to manage aHUS…
Prompt and intensive supportive care, which included plasma exchange and Soliris (eculizumab), successfully reversed organ failure and controlled atypical hemolytic uremic syndrome (aHUS) triggered by sepsis — a severe infection that can trigger widespread inflammation in the body — in a young…
Researchers have identified a potential gene therapy approach for atypical hemolytic uremic syndrome (aHUS) and C3 glomerulopathy (C3G), two kidney diseases driven by overactive complement activity, according to a new mouse study. In mouse models of both diseases, delivering the gene for the complement protein factor D to liver…
The safety and effectiveness of Ultomiris (ravulizumab-cwvz) as a maintenance therapy for children and adolescents with atypical hemolytic uremic syndrome (aHUS) remained unchanged even when the drug was administered at lower doses, not using the patient’s weight as a guide. That’s according to a new, small study that…
Leakage in an artificial heart valve appeared to trigger atypical hemolytic uremic syndrome (aHUS) in a 70-year-old woman who had no disease-related genetic mutations, a team of researchers noted in a new report, saying the case highlights the importance of a full examination for individuals suspected of having the…
Researchers reported that atypical hemolytic uremic syndrome (aHUS) is driven by abnormal activation of the alternative complement pathway, an immune response that’s independent of antibody activity, according to a study using endothelial cells that line blood vessels. These results challenge a recent report suggesting that aHUS…
Treatment with Ultomiris (ravulizumab) led to both rapid and long-lasting improvements in people with atypical hemolytic uremic syndrome (aHUS), according to a real-world study. The study found that most people who had never received a C5-inhibitor therapy before saw key blood and kidney measures return to normal. These…
A 39-year-old woman who developed a rare sequence of postpartum complications — eclampsia, HELLP syndrome, and pregnancy-associated atypical hemolytic uremic syndrome (aHUS) — recovered after doctors performed a series of emergency interventions, according to a case report from China. Postpartum eclampsia is characterized by high blood pressure and excess…
A man with atypical hemolytic uremic syndrome (aHUS) who had received a kidney transplant later developed a recurrence of the disease after testing positive for SARS-CoV-2, the virus that causes COVID-19, according to a case report. Treatment with eculizumab — available in the U.S. as Soliris and biosimilars — led…
Recent Posts
- My complicated health journey now includes post-exertional malaise
- Soliris part of strategy for complex kidney transplant in aHUS case
- My community helps me navigate the ultra-rare reality of living with aHUS
- Dual therapy manages aHUS with high blood pressure: Case report
- Caregivers are the unsung heroes of the rare disease world
- aHUS drug Soliris helps reverse organ failure in young woman in rare case
- A ‘glow-up’ is just the boost I’ve needed in life with rare diseases
- Unexpected gene therapy finding may help treat two rare kidney diseases
- How aHUS treatment led to my first tattoos
- Ultomiris at lower doses just as safe, effective for children with aHUS: Study